Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTXNASDAQ:CRISNASDAQ:NTGNNASDAQ:RGLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$21.54+0.3%$21.01$10.14▼$28.42$235.93M0.8971,327 shs50,806 shsCRISCuris$1.63+3.2%$2.18$1.02▼$16.99$13.84M3.5164,613 shs132,033 shsNTGNNeon Therapeutics$3.07$3.03$0.88▼$6.25$88.93M-0.81516,108 shsN/ARGLSRegulus Therapeutics$2.76-1.4%$1.62$0.83▼$2.90$182.83M1.03700,609 shs898,023 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics+0.28%+10.80%+3.41%+13.91%+75.26%CRISCuris+3.16%+24.43%-31.80%-52.34%-88.96%NTGNNeon Therapeutics0.00%0.00%0.00%0.00%0.00%RGLSRegulus Therapeutics-1.43%+33.98%+113.95%+122.58%+24.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDTXCidara Therapeutics4.3168 of 5 stars4.62.00.04.63.40.80.0CRISCuris2.2742 of 5 stars3.53.00.00.02.20.01.3NTGNNeon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARGLSRegulus Therapeutics3.5131 of 5 stars3.55.00.00.04.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTXCidara Therapeutics 3.25Buy$39.1481.72% UpsideCRISCuris 3.00Buy$21.001,188.34% UpsideNTGNNeon Therapeutics 0.00N/AN/AN/ARGLSRegulus Therapeutics 3.00Buy$12.75361.96% UpsideCurrent Analyst Ratings BreakdownLatest CRIS, CDTX, NTGN, and RGLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.003/31/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $16.003/27/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.003/17/2025RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/14/2025RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/12/2025CDTXCidara TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/12/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$46.003/12/2025CDTXCidara TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.003/10/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $35.003/7/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.002/26/2025RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTXCidara Therapeutics$1.28M185.04N/AN/A($1.82) per share-11.84CRISCuris$10.91M1.27N/AN/A$3.34 per share0.49NTGNNeon TherapeuticsN/AN/AN/AN/A$0.50 per shareN/ARGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTXCidara Therapeutics-$22.93M-$30.09N/AN/AN/A-289.05%-69.64%-33.73%4/28/2025 (Estimated)CRISCuris-$47.41M-$7.03N/AN/AN/A-443.35%-923.37%-78.35%5/6/2025 (Estimated)NTGNNeon Therapeutics-$79.78M-$2.86N/AN/AN/AN/A-199.09%-137.14%N/ARGLSRegulus Therapeutics-$30.04M-$0.87N/AN/AN/AN/A-53.07%-48.58%5/8/2025 (Estimated)Latest CRIS, CDTX, NTGN, and RGLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45N/AN/AN/AN/AN/A5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.33N/AN/AN/AN/AN/A5/6/2025Q1 2025CRISCuris-$1.39N/AN/AN/A$2.37 millionN/A3/31/2025Q4 2024CRISCuris-$1.36-$1.25+$0.11-$1.25$2.04 million$2.70 million3/20/2025Q4 2024RGLSRegulus Therapeutics-$0.20-$0.20N/A-$0.20N/AN/A3/6/2025Q4 2024CDTXCidara Therapeutics-$5.28-$5.38-$0.10-$5.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTXCidara TherapeuticsN/AN/AN/AN/AN/ACRISCurisN/AN/AN/AN/AN/ANTGNNeon TherapeuticsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTXCidara TherapeuticsN/A3.543.54CRISCurisN/A1.221.22NTGNNeon Therapeutics0.431.583.00RGLSRegulus TherapeuticsN/A14.1514.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTXCidara Therapeutics35.82%CRISCuris29.97%NTGNNeon Therapeutics54.71%RGLSRegulus Therapeutics92.38%Insider OwnershipCompanyInsider OwnershipCDTXCidara Therapeutics7.64%CRISCuris5.70%NTGNNeon Therapeutics38.93%RGLSRegulus Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTXCidara Therapeutics9010.95 million6.51 millionNo DataCRISCuris608.49 million7.98 millionNo DataNTGNNeon Therapeutics10228.97 millionN/ANot OptionableRGLSRegulus Therapeutics3066.24 million62.65 millionOptionableCRIS, CDTX, NTGN, and RGLS HeadlinesRecent News About These CompaniesShould You Buy Regulus (RGLS) After Golden Cross?April 24 at 10:55 AM | zacks.comRegulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above 200 Day Moving Average - Time to Sell?April 24 at 4:39 AM | marketbeat.comShort Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 30.4%April 21, 2025 | marketbeat.comIs Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | insidermonkey.comIs Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comWhy Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 5.41%April 18, 2025 | aaii.comWhy Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 7.85%April 15, 2025 | aaii.comRegulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?April 14, 2025 | marketbeat.comRegulus Therapeutics Inc (RGLS)April 10, 2025 | uk.investing.comRegulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?April 5, 2025 | marketbeat.comWhy Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 12.00%April 3, 2025 | aaii.comRegulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech SummitApril 2, 2025 | prnewswire.comRegulus Therapeutics Leads The Charge Among 3 Promising Penny StocksMarch 31, 2025 | uk.finance.yahoo.comRegulus upgraded to Overweight from Equal Weight at Wells FargoMarch 29, 2025 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)March 29, 2025 | markets.businessinsider.comRegulus jumps after data update from early-stage trial for kidney disease therapyMarch 28, 2025 | msn.comRegulus Therapeutics (NASDAQ:RGLS) Rating Increased to Overweight at Wells Fargo & CompanyMarch 28, 2025 | marketbeat.comWells Fargo Upgrades Regulus Therapeutics (RGLS)March 28, 2025 | msn.comWhy Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 16.28%March 28, 2025 | aaii.comRegulus stock surges on positive trial resultsMarch 27, 2025 | za.investing.comRegulus shares surge on Wells Fargo upgrade, clinical updateMarch 27, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRIS, CDTX, NTGN, and RGLS Company DescriptionsCidara Therapeutics NASDAQ:CDTX$21.54 +0.06 (+0.28%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$21.52 -0.02 (-0.12%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Curis NASDAQ:CRIS$1.63 +0.05 (+3.16%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.31%) As of 04/25/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Neon Therapeutics NASDAQ:NTGNNeon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Regulus Therapeutics NASDAQ:RGLS$2.76 -0.04 (-1.43%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.76 0.00 (0.00%) As of 04/25/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
